European S1 289 guideline for the treatment of hidradenitis suppurativa/acne inversa, J Eur Acad Dermatol, vol.290, pp.619-663, 2015. ,
Quality of life impairment in 292 hidradenitis suppurativa. A study of 61 cases, J Am Acad Dermatol, vol.56, pp.621-624, 2007. ,
Treatment experience in a local population 294 with hidradenitis suppurativa, J Drugs Dermatol, vol.13, pp.827-858, 2014. ,
Hidradenitis suppurativa: number of diagnosed patients, demographic 296 characteristics, and treatment patterns in the United States, Am J Epidemiol, vol.179, pp.1477-297, 2014. ,
A Retrospective Cohort Study on 299 Patients with Hidradenitis Suppurativa, Dermatology, vol.234, pp.71-79, 2018. ,
Management of hidradenitis suppurativa: a U.K. survey of current 301 practice, Br J Dermatol, vol.173, pp.1070-1072, 2015. ,
, British Association, p.303
, Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa, p.304
, Br J Dermatol, vol.180, pp.1009-1026, 2019.
North American 306 clinical management guidelines for hidradenitis suppurativa, p.307 ,
, States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and 308 systemic medical management, J Am Acad Dermatol, vol.81, pp.91-101, 2019.
,
, Consensus on the treatment of hidradenitis suppurativa -Brazilian Society of Dermatology
, An Bras Dermatol, vol.94, pp.7-19, 2019.
Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and 313 familial benign pemphigus : surgical approach ,
,
, Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with 317 an analysis of factors associated with disease severity, J Am Acad Dermatol, vol.61, pp.51-58, 2009.
, , p.319
, Unmet Needs in Hidradenitis Suppurativa: results from the Global VOICE project, J Am, vol.320
, , 2019.
,
, The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A 323
, Prospective Metagenomic Study. Clin Infect Dis, vol.65, pp.282-91, 2017.
Bacterial 325 pathogens associated with hidradenitis suppurativa, france, Emerg Infect Dis, vol.20, pp.1990-1998, 2014. ,
, The Follicular Skin, vol.327
, Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls, JAMA 328 Dermatol, vol.153, pp.897-905, 2017.
Efficacy 330 of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa, Dermatology, vol.222, pp.49-58, 2011. ,
,
, Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 334 update by the infectious diseases society of America, Clin Infect Dis, vol.59, pp.147-59, 2014.
The French version of Skindex 336 (Skindex-France). Adaptation and assessment of psychometric properties ,
, Ann Dermatol 337 Venereol, vol.130, pp.177-83, 2003.
Objective scoring of hidradenitis 339 suppurativa reflecting the role of tobacco smoking and obesity, Br J Dermatol, vol.161, pp.831-340, 2009. ,
Modifications to the Sartorius score and instructions for evaluating the severity 342 of suppurative hidradenitis ,
, Ann Dermatol Venereol, vol.134, pp.173-177, 2007.
Topical clindamycin versus systemic tetracycline in the 344 treatment of hidradenitis suppurativa, J Am Acad Dermatol, vol.39, pp.971-975, 1998. ,
, Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin, Int J 346 Dermatol, vol.22, pp.325-333, 1983.
Clindamycin and rifampicin combination therapy for 348 hidradenitis suppurativa, Br J Dermatol, vol.154, pp.977-985, 2006. ,
Combination 350 therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 351 consecutive patients, Dermatology, vol.219, pp.148-54, 2009. ,
The effect of combined treatment with oral 353 clindamycin and oral rifampicin in patients with hidradenitis suppurativa, Dermatology, vol.354, pp.143-150, 2009. ,
The effect of oral clindamycin and rifampicin combination 356 therapy in patients with hidradenitis suppurativa in Singapore, Clin Cosmet Investig Dermatol, vol.357, pp.37-46, 2018. ,
,
, Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: 360 Clinical and ultrasound observations, J Am Acad Dermatol, vol.80, pp.1314-1335, 2019.
Oral clindamycin and 362 rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 363 patients, J Eur Acad Dermatol Venereol, vol.28, pp.125-131, 2014. ,
Oral clindamycin and 365 rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year 366 follow-up, Clin Exp Dermatol, vol.41, pp.852-859, 2016. ,
Clindamycin alone may be enough. Is it time to abandon 368 rifampicin for hidradenitis suppurativa?, Br J Dermatol, vol.180, p.1262, 2019. ,
Hidradenitis 370 suppurativa treated with tetracycline in combination with colchicine: a prospective series of 371 20 patients, Int J Dermatol, vol.56, pp.346-50, 2017. ,
Community faecal 373 carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French 374 children, BMC Infect Dis, vol.12, p.315, 2012. ,
The 376 microbiome of tunnels in hidradenitis suppurativa patients, J Eur Acad Dermatol Venereol, vol.377, pp.1775-80, 2019. ,
, Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired 379 respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic 380 characteristics, Pharmacotherapy, vol.20, pp.245-56, 2000.
, , p.382
, Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa 383
, Age of patients (years), median
, Body mass index (kg.m -2 ), median
, Familial HS
, Age at onset of HS (years), median
, Duration of HS (years), median
, Patients with ? 1 flare/month, n (%) 23 (82) 409 N° of HS active lesions
,
, Antibiotics, issue.89, p.25
, Rifampicin-clindamycin, n (%)
, , p.14
, Tetracycline, issue.39, p.11
, Reported use of non-steroidal anti-inflammatory drugs, n (%)
, Local surgery, n (%), p.27
, Wide surgery, n (%), p.10